Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck


This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the head and neck (HNSCC).

Study Start Date

May 2015

Estimated Completion Date

May 2017


  • Drug: Intraarterial Cetxuimab (Erbitux)


  • Internal Medicine: Hematology/Oncology
  • Oncology: Head and Neck
  • Otolaryngology: Head and Neck

MeSH Terms

  • Carcinoma, Squamous Cell
  • Head and Neck Neoplasms

Study ID

North Shore Long Island Jewish Health System -- 15-182



Trial ID


Study Type


Trial Phase

Phase 1

Enrollment Quota



North Shore Long Island Jewish Health System

Inclusion Criteria

    1. Male or female patients of ?18 years of age. 2. Patients with a documented diagnosis of recurrent head and neck squamous cell carcinoma Patients must have at least one confirmed and evaluable tumor site.* The recurrence must have bidimensional measurements by clinical examination or CT scan. A confirmed recurrence site may also be biopsy-proven 3. Tumor Recurrence which is surgically unresectable (Appendix) 4. Patients must have a Karnofsky performance status ?70% (or the equivalent ECOG level of 0-2) (see Appendix Performance Status Evaluation) and an expected survival of ? three months. 5. Patients must have adequate hematologic reserve with WBC?3000/mm3, absolute neutrophils ?1500/mm3 and platelets ?100,000/ mm3. Patients who are on Coumadin must have a platelet count of ?150,000/ mm3 6. Pre-enrollment chemistry parameters must show: bilirubin<1.5X the institutional upper limit of normal (IUNL) AST or ALT<2.5X IUNL and creatinine<1.5X IUNL. 7. Pre-enrollment coagulation parameters (PT and PTT) must be ?1.5X the IUNL. 8. Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study. 9. Patients must be able to understand and give written informed consent. Informed consent must be obtained at the time of patient screening. 10. Patients who refuse surgery.

Exclusion Criteria

    1. Women who are pregnant or lactating. 2. Women of childbearing potential and fertile men will be informed as to the potential risk of procreation while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period. 3. Patients with significant intercurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring. 4. Pre-existing cardiac or respiratory disorders 5. Unrelated malignancy within 3 years 6. History of hypersensitivity reactions to other EGFR inhibitors 7. Metastatic disease 8. Less than 6 months from prior Radiation Therapy (Arm 1) 9. Previous exposure to Cetuximab




18 Years and older

Accepts Healthy Volunteers


Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Lenox Hill Hospital - New York, New York 47.8 miles John Boockvar MD 212-434-3900 provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.